Recent Updates
Recently added Catalysts
IRWD Positive Sentiment

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Thursday, April 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ironwood Pharmaceuticals will present findings from its LANDMARK survey at the 2026 Digestive Disease Week. The focus will be on healthcare professionals' perspectives regarding the burden of total parenteral nutrition in patients with short bowel syndrome. This presentation aims to shed light on critical insights that could influence treatment approaches.
Price reaction · baseline $4.18 (2026-04-22 close) · hit after-hours · clean, no other IRWD news in the window
day 0 close · peak
-9.3%
day 1
-6%
day 3
+0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Ironwood Pharmaceuticals is actively engaging with healthcare professionals.
  • The presentation will provide valuable insights on total parenteral nutrition.
  • The LANDMARK survey highlights important data for short bowel syndrome.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present data from its LANDMARK survey during the 2026 Digestive Disease Week® (DDW) meeting being held from May 2-5 in Chicago, IL. The data will spotlight healthcare professional (HCP) insights on the burden of total parenteral nutrition (TPN) f

Frequently Asked Questions

What will Ironwood present at DDW 2026?

Ironwood will present data from its LANDMARK survey focusing on TPN burden.

What is the LANDMARK survey about?

The LANDMARK survey gathers insights from healthcare professionals on TPN in SBS.

When is the Digestive Disease Week 2026?

The Digestive Disease Week 2026 will take place from May 2-5 in Chicago, IL.

Who will benefit from the insights shared?

Healthcare professionals and stakeholders in gastrointestinal treatments will benefit.

ShareAdd on Google
Tags: IRWD Viatris Investor Conferences Healthcare Ironwood Pharmaceuticals total parenteral nutrition short bowel syndrome LANDMARK survey Digestive Disease Week
Last updated: Apr 23, 2026

Biotech snapshot

Cash runway
$79M liquidity · $0M/mo burn
Low dilution risk
Lead asset
IW-3718Phase 3
Gastroesophageal Reflux Disease (GERD) →

Catalyst track record

+57%
best trade around IRWD's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for IRWD.

See every catalyst's timing & PoA →